Unlike targeted anti-melanoma drugs that tend to be more effective for either BRAF-mutant or NRAS-wildtype cell lines (Supplementary Fig. 17), cladribine and other predicted drugs show good efficacy regardless of the mutation status with narrow IC50 ranges (see Supplementary File 2 for the IC50 values found in the databases and the literature and additional information on clinical trials). The gene discussed is BRAF; the disease is melanoma.